The Brazilian Pharmaceutical Market Still Has Much to Learn from the United States

Whenever we discuss generic medicines, the conversation usually revolves around quality, bioequivalence, or regulatory requirements. In my view, however, the greatest difference between Brazil and the United States is not science—it is the market itself.

Both countries have highly respected regulatory agencies. Brazil's National Health Surveillance Agency (ANVISA) and the U.S. Food and Drug Administration (FDA) require generic medicines to demonstrate that they meet the applicable regulatory standards before reaching patients. Suggesting that one system is inherently more rigorous than the other oversimplifies a far more complex reality.

The real distinction becomes clear when we examine the business environment.

In the United States, competition is at the heart of the pharmaceutical industry. Once patent protection and regulatory exclusivities expire, multiple manufacturers rapidly enter the market. The result is intense competition based on price, product availability, manufacturing efficiency, and supply chain performance.

Competition is not viewed as a threat—it is viewed as the engine that drives affordability, innovation, and continuous improvement.

Brazil follows a different path.

Over the past twenty-five years, generic medicines have transformed access to healthcare and significantly expanded treatment options for millions of patients. Nevertheless, the Brazilian market remains comparatively more concentrated, and the entry of new competitors is often slower than in the United States.

This difference has important consequences.

A less competitive environment generally leads to fewer manufacturers, slower price reductions, and, in some therapeutic areas, greater vulnerability to supply shortages.

In my opinion, Brazil's biggest challenge is no longer regulatory.

It is economic.

For many years, much of the Brazilian pharmaceutical industry has been primarily focused on serving the domestic market. In contrast, many American pharmaceutical companies are structured from day one with international expansion in mind.

This global mindset influences virtually every business decision—from manufacturing capacity and technology investments to logistics, regulatory strategy, and product development.

Another striking difference is speed.

In the United States, companies often prepare years in advance for patent expiration. Development programs begin early, manufacturing is scaled before launch, and regulatory submissions are carefully planned so products can enter the market as soon as legally possible.

The competitive race starts long before the patent expires.

In Brazil, commercialization often follows a more gradual timeline. While the regulatory framework is robust, market dynamics tend to produce a slower expansion of competition after exclusivity ends.

Technology is another area where the gap becomes evident.

American pharmaceutical companies have invested heavily in automation, artificial intelligence, advanced manufacturing, predictive analytics, and digital supply chain management.

Operational excellence is treated as a strategic competitive advantage—not merely as a compliance requirement.

Brazil has made significant progress in pharmaceutical manufacturing and quality systems. The country is home to highly qualified professionals and internationally recognized manufacturers. However, I believe there is still considerable room to accelerate the adoption of digital technologies, AI-driven decision-making, and data-centric manufacturing strategies.

This is not a criticism.

It is an opportunity.

Brazil has already demonstrated that it can manufacture high-quality medicines that meet demanding regulatory standards.

The next step is to strengthen its position as a global pharmaceutical player.

That requires looking beyond the domestic market.

It requires building companies capable of competing internationally—not only on quality, but also on innovation, operational efficiency, technology, and execution.

The pharmaceutical industry is becoming increasingly global.

Supply chains cross continents.

Manufacturing is international.

Innovation is collaborative.

Artificial intelligence is reshaping research, development, quality management, and regulatory affairs.

Companies that embrace this transformation will define the next generation of pharmaceutical leadership.

Ultimately, I believe the greatest difference between the Brazilian and American pharmaceutical markets is not regulatory—it is cultural.

The United States has built an ecosystem where competition drives continuous evolution.

Brazil has already built the technical foundation.

Now it has the opportunity to build the global ambition.

And I believe that journey has only just begun.